News 2024-09-09
Join Porton and Industry Elites at Pharma Crystallization Summit 2024!
As a proud gold sponsor of the Pharma Crystallization Summit 2024 (PCS 2024), the Crystallization Team at Porton, with locations in New Jersey (USA) and Shanghai (China), offers expert services in polymorph discovery and selection, crystallization process development, particle engineering, DS-DP co-processing, and pre-formulation evaluation.
The technical experts from Porton, Dr. Jian Wang and Dr. Yuriy Abramov, will serve as forum hosts and participate in the entire event. We invite industry elites from around the world to join us at the Crowne Plaza Hotel in Princeton, New Jersey, USA.
Conference Highlights
Convene Pioneers in Drug R&D and Top Crystallization Experts from Industry and Academia
Including representatives from Pfizer, AbbVie, Amgen, Eli Lilly & Co, Merck, GSK, as well as Carnegie Mellon University, Imperial College, and Rowan University.
Features a New Technical Solution Poster Session
Offering attendees more opportunities to engage face-to-face with top experts and diverse solution providers in the industry.
Wide Coverage of the Agenda
Covering core topics throughout the entire drug development lifecycle, from fundamental scientific research to industrial application, aiming to provide efficient technological solutions for challenges at different stages of new drug development.
Industry Pain Point Solutions
Helping crystallization and formulation solution providers accurately address industry pain points and efficiently offer customized solutions, jointly driving innovation and development in pharmaceutical crystallization technology.
Agenda
Honored Speaker
Register NOW to join industry elites at the premier crystallization event!
Please follow this registration link:
https://crystallizationsummit.com/2024-2/2024-registration/
-
Sponsors continually being added
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
